OXFORD, UK, July 21st, 2016

PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates.

The new firm, which is 100% owned by PharmaVentures, will be able to expand our client offering to include: publice transactions; certain transactions involving listed companies; and fund raising. 

Fintan Walton, Chief Executive of PharmaVentures said: “We are delighted to expand our offering to clients through this new FCA regulated firm as it is quite common for our clients to require a broader range of corporate finance advice”.

Those authorised to conduct regulated work include Fintan Walton, Chairman and Chief Executive, Stephen Waterman and Ping Shek, all of whom are Board Directors of PharmaVentures Capital Ltd. and Issac Jacob, Senior Director at PharmaVentures Ltd.

The Financial Conduct Authority is the major financial regulatory body in the UK which regulates the financial services industry in the UK. Its role includes protecting consumers, keeping the industry stable, and promoting healthy competition between financial service providers. The UK is one of the leading centres for financial services in the world.

For the past 24 years, PharmaVentures has acted as an advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activites for companies.

OXFORD, UK, March 22nd, 2016.

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. (To read the admission document, download the PDF)

SalvaRx is an immuno-oncology company developing novel therapeutics that stimulate the immune system to fight cancer. SalvaRx also owns over 60% of iOx Therapeutics, which is developing anti-cancer treatments based on invariant natural killer T-cells and is poised to undertake the first Phase I/II human trials.

Adrian Dawkes, Vice President, PharmaVentures said; “In the pivotal area of immuno-oncology we were pleased to be able to provide an expert assessment of the iOx technology to support 3Legs in its acquisition.”

Fintan Walton, Chief Executive of PharmaVentures said: “This is the twelfth independent expert report we have provided for companies raising finance, and the third during the recent upturn in IPO activities in the UK. Expert commercial and technical insight is a key component in company acquisitions especially where public markets are involved. PharmaVentures is able to provide valuable advisory services for our clients via our deep knowledge of the pharmaceutical and biotechnology sectors.”

OXFORD, UK, February 4th, 2016.

PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.

Transgene (Euronext: TNG), a member of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases.

ABL, also a member of Institut Mérieux, is a leading US contract research and manufacturing organisation. The Strasbourg acquisition will enable the company to establish ABL Europe and to increase its capabilities as a contract manufacturer with a stronger foothold within European Union.

Nigel Borshell, Vice President of PharmaVentures said: “We are delighted to have helped Transgene find a buyer for their biopharmaceutical manufacturing facility and to see its continued operation by ABL as a strategic and high value asset”.

Fintan Walton, Chief Executive of PharmaVentures said: “Yet again the successful sale of this manufacturing facility in France shows that PharmaVentures is a leader in finding buyers for pharmaceutical companies wishing to divest assets.”

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

Oxford, UK, 17^th December, 2015.

PharmaVentures is pleased to announce that it acted as advisor to Stericool on its sale to Sweden’s Getinge Group, a global leader in infection control and contamination prevention solutions.

Stericool specialises in hydrogen peroxide based solution low temperature sterilizers for emerging markets.  Founded in 2008, Stericool has its headquarters and manufacturing site in Ankara, Turkey. The acquisition will be included under Getinge’s new business category unit Surgical Workflows and will increase potential for growth in East/ South Europe and the rest of the world.

Fintan Walton, Chief Executive of PharmaVentures said: “This is another important cross-border result for one of our clients. PharmaVentures continues to provide valuable advisory services across healthcare M&A and Licensing”.

Ping Shek, Vice President of PharmaVentures said: “Medical device and healthcare equipment groups remain active in M&A as adding complementary businesses to their global platforms augments organic growth”.

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

Oxford, UK, 16^th September 2015:

PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR). NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer.  It’s proprietary urine-based, molecular biomarker test for prostate cancer offers a low cost “liquid biopsy” method to identify patients at low risk for prostate cancer. This mRNA biomarker test can also help identify men at increased risk of high-grade disease who may benefit most from a prostate biopsy procedure.

Nigel Borshell, Vice President, PharmaVentures, Ltd said: “We are delighted to support NovioGendix and its shareholders in achieving an exit.”

Fintan Walton, Chief Executive, PharmaVentures, Ltd said: “This is another important result for one of our clients. PharmaVentures has established itself as a leading an advisor in M&A and Licensing”.

For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.